Clinical trial
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With…
NCT00354185 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00354185 |
|---|---|
| Title | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma |
| Official title | A Phase I Study of PXD101 in Combination With 17-AAG in Advanced Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma and 51 more |
| Intervention type | Drug, Other |
| Interventions | tanespimycin, belinostat, laboratory biomarker analysis, pharmacological study |
| Enrollment | 36 |
| Start date | May 1, 2006 |
| Primary completion | Feb 1, 2008 |
| First posted | Jul 20, 2006 |
| Last update posted | May 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: